Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed non-small cell lung cancer (NSCLC)~  * Stage IB or II disease~* Resectable disease~* At least 1 measurable lesion~* No mediastinal involvement by mediastinoscopy and/or positron emission tomography with fludeoxyglucose F 18 scan~* No evidence of metastatic disease~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Absolute neutrophil count \> 1,500/mm³~* Platelet count \> 100,000/mm³~* Hemoglobin \> 10 g/dL~* Creatinine clearance ≥ 60 mL/min~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 3.0 times ULN~* AST and ALT ≤ 3.0 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignant disease, except for the following:~  * Basocellular carcinoma of the skin~ * Adequately treated carcinoma in situ of the cervix~ * Low-grade prostate cancer~ * Other cancer for which the patient has been disease-free for ≥ 5 years~* No congestive heart failure or angina pectoris unless medically controlled~* No myocardial infarction within the past 6 months~* No uncontrolled hypertension or arrhythmia~* No active uncontrolled infection requiring antibiotics~* No illness or medical condition that would preclude study participation~* No pre-existing motor or sensory neurotoxicity ≥ grade 2~PRIOR CONCURRENT THERAPY:~* No prior surgery for NSCLC~* No prior or other concurrent chemotherapy for NSCLC~* No prior or concurrent radiotherapy for NSCLC~* No concurrent immunotherapy~* No concurrent targeted agents~* No concurrent hormonal cancer therapy~* No concurrent routine colony-stimulating factor (e.g., prophylactic filgrastim \[G-CSF\])~* No aspirin or nonsteroidal anti-inflammatory drugs within 5 days before or after chemotherapy~* No other concurrent experimental treatments~* No other concurrent anticancer treatments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).